For type 2 diabetes management , licensed GLP-1 medications include: Exenatide (Byetta, Bydureon) available as twice-daily or once-weekly formulations Liraglutide (Victoza) administered once daily Dulaglutide (Trulicity) given once weekly Semaglutide (Ozempic) administered once weekly as an injection Semaglutide (Rybelsus) taken orally once daily (for type 2 diabetes only, not licensed for weight management) For weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities, two medications hold specific licences: Liraglutide 3.0 mg (Saxenda) once-daily subcutaneous injection Semaglutide 2.4 mg (Wegovy) once-weekly subcutaneous injection Access to these medications through the NHS is governed by NICE guidance
The term "lipotropic" literally means "fat-loving" and refers to compounds that promote the transport and metabolism of fat in the body
Each named dose 2.5, 5, 7.5, 10, 12.5, 15 mg corresponds to a documented step
It promotes collagen and elastin synthesis throughout the body, supports tissue remodeling, and reduces systemic inflammation all of which contribute to a healthier scalp environment
Products may carry risks, including immunogenicity or impurities, if mishandled
WEIGHT LOSSFinancing availableProduct Information and Pricing Semaglutide Liquid GLP-1 medication for weight loss
